Introduction/Background Definitive local treatment to the primary tumor site can provide a survival benefit in stage IVB uterine cervical cancer. However, outcomes are still poor and novel prognostic factors are needed to decide for the optimal treatment. In the current study, we aimed to evaluate the oncologic outcomes and prognostic factors for patients with stage IVB cervical cancer that underwent definitive chemoradiotherapy (CRT) to the primary tumor site ± distant metastasis (DM).

Methodology Records of 14 metastatic cervical cancer patients who received definitive CRT after systemic therapy in our institution between 2016 and 2022 were retrospectively evaluated. Kaplan–Meier method was used for survival analysis (IBM SPSS 23 software) and p<0.05 was considered statistically significant.

Results Baseline patient, tumor and treatment characteristics are presented at table 1. During the median follow-up of 18 months (range, 7–62 months), local recurrence was observed in three (21%) cases and at least one new DM were observed in nine (64%) cases. For the primary disease site, the 2-year local control (LC) rate was 77%. The 2-year overall survival (OS) and DM-free survival (DMFS) rate was 52%, and 40%, respectively. DMFS rates were higher in patients with metastasis-to-tumor SUVmax ratio (MTR) ≤0.7 (64% vs. 14%, p=0.006) and SUVmax of the DM ≤12.5 (68% vs. 14%, p=0.015).

Conclusion Although LC is achieved with systemic treatment and definitive CRT in most patients, the rate of development of a new DM is quite high and there is a need for more effective systemic treatment options to improve prognosis. In addition, patients with SUVmax MTR >0.7 and SUVmax of the DM >12.5 have increased risk for development of a new DM who may be candidates for treatment intensifications after systemic therapy and CRT.

Disclosures None